Ben is a senior editor for BioPharma Dive. He is a veteran business journalist with 15 years of experience covering a variety of sectors. Prior to joining Industry Dive, Ben spent six-plus years with Xconomy writing about biotech, specializing in unique angles, profiles, features, enterprise pieces and more. A lifelong New Yorker, Brooklyn transplant and Yankees/Giants/Knicks fan, Ben is trying to cope with a recent move to the suburbs of Virginia, where he spends most of his time chasing after his rambunctious toddler. Ben has a B.A. from Binghamton University.
261 articles by Ben Fidler
-
Bristol Myers withdraws Opdivo in liver cancer as fallout from FDA meeting continues
July 26, 2021 -
A biotech's eye gene therapy faces longer odds as serious side effects pile up
July 23, 2021 -
Seres, after earlier success, fails a key test for microbiome drugs
July 22, 2021 -
Bluebird, with little fanfare, is first to bring a second gene therapy to market
July 21, 2021 -
Ardelyx latest biotech surprised by unexpected FDA criticism of drug application
July 20, 2021 -
COVID-19 drug developer Adagio plans IPO to cap fast rise
July 19, 2021 -
Merck details an immunotherapy 'milestone' in early breast cancer
July 15, 2021 -
Biogen chases rivals with another bet on emerging class of multiple sclerosis drugs
July 13, 2021 -
Celldex pins its hopes for a comeback on skin disease drug
July 9, 2021 -
FDA revises labeling of Biogen's Alzheimer's drug to emphasize early treatment
July 8, 2021 -
WHO backs Roche, Sanofi drugs for COVID-19 after research ups and downs
July 7, 2021 -
As Arrowhead falters, lungs remain a tough target for RNA drugs
July 6, 2021 -
5 FDA decisions to watch in the third quarter
July 2, 2021 -
Deals surge, returns slip: takeaways from a record half for biotech IPOs
June 30, 2021 -
Coronavirus variants deal another blow to Lilly's COVID-19 drug business
June 28, 2021 -
Intellia, with first results, delivers a 'landmark' for CRISPR gene editing
June 26, 2021 -
8 key clinical trials to watch for the rest of 2021
June 21, 2021 -
CureVac vaccine disappoints in key study amid 'unprecedented' spread of variants
June 17, 2021 -
Sage antidepressant succeeds in key study, but data raise questions
June 15, 2021 -
GSK pays iTeos $625M to join race for new type of cancer immunotherapy
June 14, 2021 -
US bets $1.2B on Merck's last hope for a COVID-19 drug
June 9, 2021 -
ASCO21: An immunotherapy debate, an NK cell question and the next precision drugs
June 7, 2021 -
An AstraZeneca, Merck drug slows the return of genetic breast cancer. Will testing speed up?
June 3, 2021 -
EQRx readies a lower-cost alternative to pricey cancer immunotherapies
May 28, 2021 -
Vir, GSK win US nod for another COVID-19 antibody drug as rival falters
May 27, 2021